Alternative Investment Market's (Aim) largest company has outgrown its original home. Medicinal marijuana specialist GW Pharmaceuticals (GWP) will delist from London's junior market on 2 December and set up camp exclusively on the tech-savvy Nasdaq index, where it has had a dual listing since 2013. Since joining Aim in 2001, GW's share price has multiplied by more than 4.5 times - pretty impressive for a company that still isn't making any money.
According to the company, 78 per cent of its shares are held as American Depository Shares (ADS) and nearly 94 per cent of its trading in the past six months took place on Nasdaq. For chief executive Justin Gover this means that "the time is right to reduce the complexity and expense of a dual listing".
